Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Beijing Funakang Biotech, operating under the brand FNAT, is a leading biotechnology company focused on the research, development, and industrialization of fullerene-based materials. The company leverages its proprietary technology to produce high-purity fullerenes (such as C60 and C70) and their derivatives, which are utilized as potent antioxidants in the pharmaceutical and cosmetic industries. FNAT's core expertise lies in the functionalization of fullerenes to enhance their water solubility and biological activity, enabling applications in neuroprotection, anti-aging, and hair growth. As a pioneer in the fullerene industry, the company provides high-quality raw materials and is advancing a pipeline of therapeutic candidates targeting oxidative stress-related conditions.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on FNAT Chemical.